Literature DB >> 11856825

The structure of S100A12 in a hexameric form and its proposed role in receptor signalling.

O V Moroz1, A A Antson, E J Dodson, H J Burrell, S J Grist, R M Lloyd, N J Maitland, G G Dodson, K S Wilson, E Lukanidin, I B Bronstein.   

Abstract

S100A12 is a member of the S100 subfamily of EF-hand calcium-binding proteins; it has been shown to be one of the ligands of the 'receptor for advanced glycation end products' (RAGE) that belongs to the immunoglobulin superfamily and is involved in diabetes, Alzheimer's disease, inflammation and tumour invasion. The structure of the dimeric form of native S100A12 from human granulocytes in the presence of calcium in space group R3 has previously been reported. Here, the structure of a second crystal form in space group P2(1) (unit-cell parameters a = 53.9, b = 100.5, c = 112.7A, beta = 94.6 degrees) solved at 2.7A resolution by molecular replacement using the R3 structure as a search model is reported. Like most S100 proteins, S100A12 is a dimer. However, in the P2(1) crystal form dimers of S100A12 are arranged in a spherical hexameric assembly with an external diameter of about 55 A stabilized by calcium ions bound between adjacent dimers. The putative target-binding sites of S100A12 are located at the outer surface of the hexamer, making it possible for the hexamer to bind several targets. It is proposed that the S100A12 hexameric assembly might interact with three extracellular domains of the receptor, bringing them together into large trimeric assemblies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11856825     DOI: 10.1107/s0907444901021278

Source DB:  PubMed          Journal:  Acta Crystallogr D Biol Crystallogr        ISSN: 0907-4449


  31 in total

Review 1.  Binding of transition metals to S100 proteins.

Authors:  Benjamin A Gilston; Eric P Skaar; Walter J Chazin
Journal:  Sci China Life Sci       Date:  2016-07-19       Impact factor: 6.038

2.  Solution structure of human Ca(2+)-bound S100A12.

Authors:  Kuo-Wei Hung; Chan-Chia Hsu; Chin Yu
Journal:  J Biomol NMR       Date:  2013-09-22       Impact factor: 2.835

Review 3.  Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer.

Authors:  Geetha Srikrishna; Hudson H Freeze
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

Review 4.  Calcium-dependent and -independent interactions of the S100 protein family.

Authors:  Liliana Santamaria-Kisiel; Anne C Rintala-Dempsey; Gary S Shaw
Journal:  Biochem J       Date:  2006-06-01       Impact factor: 3.857

5.  Ligands of the receptor for advanced glycation end products, including high-mobility group box 1, limit bacterial dissemination during Escherichia coli peritonitis.

Authors:  Marieke A D van Zoelen; Ahmed Achouiti; Ann-Marie Schmidt; Huan Yang; Sandrine Florquin; Kevin J Tracey; Tom van der Poll
Journal:  Crit Care Med       Date:  2010-06       Impact factor: 7.598

6.  Characterization and engineering of S100A12-heparan sulfate interactions.

Authors:  Xiaoxiao Zhang; Chihyean Ong; Guowei Su; Jian Liu; Ding Xu
Journal:  Glycobiology       Date:  2020-07-20       Impact factor: 4.313

Review 7.  RAGE: a novel target for drug intervention in diabetic vascular disease.

Authors:  Barry I Hudson; Ann Marie Schmidt
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

8.  The Calcium-Dependent Interaction of S100B with Its Protein Targets.

Authors:  Danna B Zimmer; David J Weber
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-08-17

9.  Transamidation by transglutaminase 2 transforms S100A11 calgranulin into a procatabolic cytokine for chondrocytes.

Authors:  Denise L Cecil; Robert Terkeltaub
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

10.  Structural and functional insights into RAGE activation by multimeric S100B.

Authors:  Thorsten Ostendorp; Estelle Leclerc; Arnaud Galichet; Michael Koch; Nina Demling; Bernd Weigle; Claus W Heizmann; Peter M H Kroneck; Günter Fritz
Journal:  EMBO J       Date:  2007-07-26       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.